ArticleInternational journal of nanomedicine2025
Construction of Baicalein-Loaded Chitosan Nanoparticles for
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanodrug Delivery Systems for Lower Respiratory Infections: Pulmonary Targeting, Anti-Infective Applications, and Translational Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: In this study, we constructed baicalein (a traditional Chinese medicine)-loaded chitosan nanoparticles (a drug-delivery system) with great biocompatibility for the remission of Methods: The nanoparticles were prepared via a one-step reaction. Baicalein-release rates were studied via ultraviolet absorption assays. Morphology was characterized using AFM and TEM. The antibacterial mechanism of the nanoparticles was studied through ONPG, crystal violet staining, and live/dead bacterial staining assays, anti-inflammatory performance investigated via ELISA and WB assays, and in vivo anti-lung-infection capacity studied via H&E staining and ELISA kits. Results: The average size of the nanoparticles was uniform (~200 nm), and the zeta potential was about 18.5 ± 0.3 mV. The encapsulation efficiency was about 40%. The release of baicalein was >80% under different temperatures and pH. Dry nanoparticles were also stable. The minimum inhibitory concentration against Conclusion: The in vitro and in vivo results demonstrate that our drug-delivery system could be an efficient platform for the remission of bacterium-induced lung infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.